Repare Therapeutics Inc.: restructuring charge — Repare Therapeutics cuts workforce ~75%, expects $21M annual savings; CMO departs

Repare Therapeutics Inc.

Board approved ~75% workforce reduction on Feb 23, 2025; affected employees notified Feb 24.
One-time cash charges: ~$7.3M severance + up to $1.4M retention costs, through Q4 2025.
Annual operating expense savings of ~$21M expected from the reorganization.
CMO Maria Koehler to depart March 31, 2025; severance includes nine months salary, $150k payment, COBRA, equity acceleration.
CFO Steve Forte gets $175k retention bonus; CSO Mike Zinda receives $150k retention bonus.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Repare Therapeutics Inc. announced a restructuring with charges of approximately $7.3 million related to employee severance payments and related costs (approximately 75%).

Type: restructuring
Charge: approximately $7.3 million related to employee severance payments and related costs
Headcount: approximately 75%

Exact text from the filing

These plans were communicated to affected employees on February 24, 2025. The Company expects to incur one-time cash charges associated with the Reorganization of approximately $7.3 million related to employee severance payments and related costs, which are expected to be incurred through the fourth quarter of 2025. In addition, the Company has committed to pay

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0001193125-25-033718

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.